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Abstract
Background: HTLV-I is associated with the development of an aggressive form of lymphocytic leukemia known as
adult T-cell leukemia/lymphoma (ATLL). A major obstacle for effective treatment of ATLL resides in the genetic
diversity of tumor cells and their ability to acquire resistance to chemotherapy regimens. As a result, most patients
relapse and current therapeutic approaches still have limited long-term survival benefits. Hence, the development
of novel approaches is greatly needed.
Methods: In this study, we found that a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP), PJ-34, is
very effective in activating S/G2M cell cycle checkpoints, resulting in permanent cell cycle arrest and reactivation of
p53 transcription functions and caspase-3-dependent apoptosis of HTLV-I-transformed and patient-derived ATLL
tumor cells. We also found that HTLV-I-transformed MT-2 cells are resistant to PJ-34 therapy associated with
reduced cleaved caspase-3 activation and increased expression of RelA/p65.
Conclusion: Since PJ-34 has been tested in clinical trials for the treatment of solid tumors, our results suggest that
some ATLL patients may be good candidates to benefit from PJ-34 therapy.
Introduction
Human T-cell leukemia virus type I (HTLV-I) is etio-
logically linked to the development of an aggressive type
of peripheral T-cell leukemia known as ATLL [1]. The
clinical course varies among infected patients and the
disease has been classified into four distinct entities:
smoldering, chronic, acute, or lymphoma [2]. Although
many features of HTLV-I biology have been discovered
[3], the treatment of the disease remains unsatisfactory,
with minimal improvements in the overall survival of
patients [4]. Overall, the current therapies used for the
treatment of ATLL patients in the acute phase have lim-
ited impact and the overall projected 4-year survival rate
of acute ATLL is around 5 % [5]. The mechanism by
which HTLV-I causes ATLL is still not fully understood,
but a latency period of several decades before the onset
of the disease suggests that long-term survival and ex-
pansion of virus-infected cells are required. Along these
lines, we have previously shown that reactivation of
telomerase activity is one of the essential steps in the
transformation process of HTLV-I-infected cells [6].
HTLV-I transformed CD4/CD25+ T cells in vivo and in
vitro. In early stages, infected cells may rely on an auto-
crine/paracrine IL-2/IL-2R or IL-15/IL-15R cytokine
loop for active proliferation [7]. During that stage,
HTLV-I-infected cells accumulate genetic and epigenetic
mutations and are prone to genomic instability. At the
basis of this phenomenon is the viral oncoprotein Tax,
which has been shown to inactivate tumor suppressors
such as p16ink, p53, RB, and p21WAF [8], affect gen-
ome stability [9], and activate oncogenic signaling path-
ways such as NF-κB, Notch, and JAK/STAT [10–12]. In
addition, Tax also induces DNA breaks during cellular
replication and inhibits DNA repair pathways, leading to
accumulation of genetic alterations [13, 14]. Eventually,
an infected IL-2-independent transformed cell emerges
with a selective growth advantage resulting in clonal ex-
pansion. The molecular basis for IL-2 independence is still
unknown although a majority of HTLV-I-transformed
cells simultaneously acquire constitutive JAK/STAT acti-
vation. The transition from IL-2 dependent to IL-2 inde-
pendent is believed to mimic the disease progression from
smoldering or chronic to the acute type of ATLL.
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Recently, we showed that Tax can induce genomic DNA
double-strand breaks (DDSB) by targeting the fork of
replication during cell division [13]. Since HTLV-I-
transformed cells have a defective homologous recombin-
ation repair (HR) pathway [14], we hypothesized that
HTLV-I-transformed and ATLL cells might be particularly
sensitive to small drug inhibitors targeting DNA replica-
tion. Although poly (ADP-ribose) polymerase (PARP) is a
single-strand break sensing protein, PARP inhibitors
(PARPi) have been shown to be selectively effective in cells
with an HR-defective pathway [15]. Numerous PARPi (PJ-
34, MK4827, ABT-888, AZD2281, and BSI-201) are in
clinical trials for breast cancer, ovarian cancer, and pros-
tate cancer [16, 17]. The PARPi PJ-34 has been shown to
cause cell cycle arrest in various human cancers, including
myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML) [18, 19].
In this study, we investigated the efficacy of the PARPi
PJ-34 in targeting HTLV-I-transformed cells and a panel
of patient-derived ATLL cell lines. Our results demon-
strate that PJ-34 used as a single agent is a potent inhibi-
tor of cellular growth in IL-2-dependent as well as IL-2-
independent transformed ATLL cells. We also found
that another PARPi (olaparib/AZD2281) is also effective
against HTLV-I-transformed cells. We further show that
cells treated with PJ-34 reactivated p53 functions and ac-
cumulated in G2/M. Tumor cells died from apoptosis as
shown by annexin V staining but this process appears to
be largely p53 - independent since ATLL-derived cells
not expressing p53 (MT-1 and ED) were still efficiently
killed by PJ-34. We found that HTLV-I-transformed
MT-2 and C91PL cell lines were resistant to PJ-34 treat-
ment. We found that PJ-34-resistant cells expressed
higher basal levels of Bax and were unable to engage the
cleavage of pro-caspase-3. In addition, resistance of MT-
2 cells was independent from p53BP1 and PARP1 but
coincides with activation of NF-κB.
Materials and methods
Cell lines and reagents
HTLV-I-transformed cell lines (MT-4, MT-2, C8166,
C91PL) and ATL-like cell lines, IL-2 independent (MT-
1, ATL-T, ED-40515(−), ALT-25), were maintained in
RPMI-1640 media supplemented with 10 % FBS, peni-
cillin, and streptomycin. ATL-like cell lines, IL-2
dependent (ATL-43T, KOB, and ATL-55T), were main-
tained in RPMI-1640 supplemented with 10 % FBS,
penicillin, and streptomycin and IL-2 (50 U/mL). PARP-
1 inhibitor, PJ-34 (N-(5, 6-Dihydro-6-oxo-2-phenanthri-
dinyl)-2-(dimethylamino) acetamide, ab120981), was
purchased from Abcam. Stock solutions (25 mM) were
made with dimethyl sulfoxide (DMSO). In all experi-
ments, cells were treated with different concentrations
of PJ-34 (5, 10, 25, and 50 μM) or DMSO for 3 or 5 days,
as indicated. Olaparib was used at 25 μM for 3 days. Cell
Proliferation Kit II (XTT) was purchased from Roche
Life Science.
Cell cycle and cell proliferation
HTLV-I-transformed and ATL cells were treated with
DMSO or PJ-34 for 3 days. The cells were collected and
washed with 1× PBS and fixed with 75 % EtOH over-
night at −20 °C. The next day, cells were washed with
ice-cold 1× PBS, followed by treatment with RNase for
15 min at 37 °C, stained with 100 μg/mL propidium iod-
ine (PI) for 15 min at room temperature, and analyzed
by flow cytometry. Cell proliferation was measured by
the XTT assay. For the XTT assay, 100 μL (10,000) cells
were seeded in 96-well plates and treated with different
concentrations of PJ-34 (5, 10, 25, and 50 μM) or DMSO
for 5 days. A 50-μL of XTT labeling mixture was added
to each well and incubated for 6 h. The absorbance was
measured at 450 and 620 nm by spectrophotometry. Re-
sults were plotted as mean ± SD from at least two inde-
pendent experiments.
Cell tracking assay
CFDA-SE (Molecular Probes, Eugene, OR) was used to
label cells according to the manufacturer’s protocol.
After labeling, 1 × 105 cells were analyzed by FACS assay
for 0 h control. The rest of the labeled cells were divided
into two groups: one treated with DMSO, the other one
with PJ-34. Every 24 h, 1 × 105 cells were taken out for
FACS assay until 72 h.
Apoptosis assays and mitochondrial membrane potential
The cells were collected and washed with 1× PBS then
stained with annexin V/propidium iodide using the
Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis Kit
(Molecular Probes, Eugene, OR) according to the manu-
facturer’s instructions. MT-4, C91PL, and MT-2 cells
were treated with DMSO or PJ-34. Then, the cell mito-
chondrial membrane potential (ΔΨm) was measured
using the JC-1 Assay Kit (Invitrogen) according to the
manufacturer’s instructions.
Western blotting
Total cell extracts were prepared with RIPA buffer
(50 mM Tris HCl pH 8.0, 150 mM NaCl, 1 % NP-40,
0.5 % sodium deoxycholate, 0.1 % SDS). Samples were
separated on SDS-PAGE followed by electroblotting to
polyvinylidene difluoride membranes. The following
antibodies were used: cyclin E (C-19), cyclin A (h432),
cyclin B1 (H-20), p21 (C-19), actin (C-11) and p53 (FL-
393), Bcl-2 (100), Bax (N-20), Bcl-xS/L (S-18), caspase-8
(H-134), and caspase-3 (H-60) are all from Santa Cruz
Biotechnology; Phospho-Histone H2A.X (Ser139) (p-
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H2AX, 2577) and Phospho-p53 (Ser15) (pS15-p53,
D4S1H) are from Cell Signaling Biotechnology.
Real-time RT-PCR
Total RNA was prepared with TRIzol reagent (Invitro-
gen, Carlsbad, CA). After DNase I treatment, the RNA
was reverse transcribed and the cDNA was used for
PCR and real-time PCR. The real-time PCR assay was
performed using the iTaq™ Universal SYBR® Green
Supermix. Real-time PCR was used to detect the expres-
sion of Bax, MDM2, GADD45α, XIAP, FLIP, p53BP1,
BRCA1, p65/RELA, and PARP1. Real-time PCR was per-
formed in duplicate, and data were normalized to
GAPDH expression.
Results
PJ-34 induces cell cycle arrest in HTLV-I-transformed and
ATLL-derived cell lines
HTLV-I-transformed and ATLL cells are characterized
by excessive chromosomal instability associated with de-
fects in HR DNA repair pathways. We, therefore, hy-
pothesized that these cells might be particularly sensitive
to PARPi. HTLV-I-transformed T-cell lines MT-2, MT-4,
C8166, and patient-derived ATLL cell lines ED and
ATL-25 were treated with PJ-34 for 3 days and cell cycle
was analyzed by propidium iodide staining and DNA
content analyses on live gated cells by FACS. Our results
revealed a marked increase of cells in the G2/M phase
of cell cycle following treatment (Fig. 1a, b). These re-
sults are consistent with previous findings that the mi-
totic spindle checkpoint is functional in HTLV-I-
transformed and Tax-expressing cells, which arrest in
G2/M following treatment with NU7026, Taxol, or
Nocodazole [20, 21]. We next used carboxyfluorescein
succinimidyl ester (CFSE) incorporation and confirmed
that HTLV-I-transformed MT-2 cells treated with PJ-34
are no longer dividing (Fig. 1c), suggesting that these
cells are arrested in all the different phases of the cell
cycle. Consistent with these results, we observed a sig-
nificant increase in cyclin-dependent kinase inhibitor
(CDK) p21WAF expression in MT-2, C91PL, and MT-4
cells after treatment with PJ-34 (Fig. 1d). Cyclin A asso-
ciates with CDK2 and is involved in the initiation and
completion of DNA replication during S phase [22]. Our
experiments revealed a significant decrease in cyclin A
expression after treatment with PJ-34. Since cyclin A is
also important for centrosome replication and G2/M
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Fig. 1 PJ-34 induces S/G2M cell cycle arrest. a Cell cycle analysis of HTLV-I-transformed and ATL cells after DMSO or PJ-34 treatment. b Cell cycle
profile of DMSO- or PJ-34-treated cells. c Cell tracking of MT-2 with CFDA-SE after DMSO or PJ-34 treatment. Representative results are shown
here. d Western blot of cyclin E, cyclin A, cyclin B1, and p21 in MT-2, MT-4, and C91PL cells after DMSO or 25 μM PJ-34 treatment. Actin was used
to confirm equal loading
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for G2/M arrest observed in most cells after treatment
with PJ-34. In contrast, cyclin E, involved in G1 exit and
initiation of S phase [24], was downregulated by PJ-34 in
C91PL cells only (Fig. 1d). We next investigated the ex-
pression of Cyclin B1 because of its role in mitosis
[25]. We found that cyclin B1 expression was signifi-
cantly reduced in MT-2 and C91PL but not in MT-4
transformed cells (Fig.1d). Overall, our results suggest
that PARPi PJ-34 affects multiple cyclins and is effect-
ive in preventing proliferation of HTLV-I-transformed
cells.
Next, we measured quantitative inhibition of cellular
proliferation using XTT assays, a colorimetric assay for
the quantification of cellular proliferation. These assays
were performed in four HTLV-I-transformed cells and
seven ATLL-derived cell lines and a dose increase of PJ-
34 (5–50 μM) or DMSO vehicle as a control (Fig. 2). To
demonstrate specificity of PJ-34, we used human PBMCs
from a HTLV-I-negative healthy donor. These studies
demonstrate that IC50 for most HTLV-I-transformed or
ATL cells is around 10 μM (MT-1 and C91PL 20 μM)
(Fig. 2). Even at 50 μM of PJ-34, PBMCs present less
than 25 % inhibition when most HTLV-I-transformed
cells had more than 80 % inhibition (Fig. 2).
PJ-34 induces p53-dependent and p53-independent
apoptosis in HTLV-I-transformed and ATLL-derived cell
lines
PARPi have been used to induce apoptosis in breast cancer
and ovarian cancer cells [26–28]. The lack of effective ther-
apy for ATLL prompted us to investigate the cytotoxicity
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Fig. 2 a PBMCs, HTLV-1-transformed (C8166, MT-2, C91PL, MT4), and (b) ATL cells (ATL-MT-1, ATL-ED, ATL-KOB, ATL-T, ATL-43T, ATL-25, ATL-55T)
were treated with DMSO or different concentrations of PJ-34 (5, 10, 25, 50 μM) for 5 days; cell proliferation was measured using XTT assay. Results
were plotted as mean ± SD from at least two independent experiments
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derived cell lines. Cells were treated for 5 days and ana-
lyzed by annexin V staining. Our results demonstrated a
significant level of apoptosis in all patient-derived ATLL
cell lines and most HTLV-I-transformed cell lines, with the
exception of C91PL and MT-2 which appear to be resistant
to PJ-34-induced apoptosis (Fig. 3a, b). These results were
confirmed using a dose-dependent increase of PJ-34 on
HTLV-I-transformed MT-4 cells (Fig. 3c). To confirm spe-
cific effects of PJ-34 on HTLV-I-transformed cells, we used
a dose-dependent increase of PJ-34 and normal human
PBMCs as a negative control (Fig. 4). Overall, these studies
confirmed our previous observations and showed that
HTLV-I-transformed cells are more sensitive than PBMC
controls (Fig. 4). Also in agreement with above-mentioned
data, C91PL had kinetics similar to PBMC and MT-2 was
resistant to PJ-34 even at a dose of 50 μM (Fig. 4). Interest-
ingly, another PARPi, olaparib (AZD2281), also induced
apoptosis in HTLV-I-transformed MT-4 and ATL-ED
resulting in only 34 and 10 % live cells, respectively, after 3
days of treatment. In contrast, similar to PJ-34, MT-2 cells































DMSO PJ-34 25 µM  PJ-34 10 µM  PJ-34 5 µM  
Fig. 3 PJ-34 induces cell apoptosis in most HTLV-I-transformed and ATL cells except for C91PL and MT-2 cells. a HTLV-1-transformed and (b) ATL
cells were treated with 25 μM PJ-34 for 3 days. Cells were subsequently stained for annexin V and PI and analyzed for apoptosis by FACS analysis.
c MT-4 cell line was treated with DMSO or different amounts of PJ-34 (5, 10, 25 μM). Cells were subsequently stained for annexin V and PI and
analyzed for apoptosis by FACS analysis
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PJ-34 treatment leads to reactivation of p53 functions in
HTLV-I-transformed cells
As a result of PARP inhibition by PJ-34, unrepaired
single-strand DNA breaks (SSB) are converted into
double-strand breaks (DDSB) at fork replication and
result in accumulation of DDSB and p-H2AX foci.
Consistent with this notion, we found an increased p-
H2AX expression in cells treated with PJ-34 (Fig. 6a).
Accumulation of p-H2AX is known to result in
ATM/ATR activation and downstream Chk1-p53
pathway. Indeed, treatment of HTLV-I-transformed
cells with PJ-34 caused an increased p-p53 at serine
15 and p21WAF (Fig. 6a), suggesting that p53 may be
active in these cells. Drug cytotoxicity is often
associated with activation of p53-dependent apoptosis,
and tumors with mutated inactive p53 are frequently
resistant to radio- and chemotherapy. HTLV-I-
transformed cells in vitro and in vivo have been
shown to express high levels of p53 that is genetically
or functionally inactivated [29–31] but can be reacti-
vated leading to either apoptosis or senescence of
HTLV-I-transformed cells [32]. We compared activa-
tion of p53-mediated transcription in MT-4 (PJ-34
sensitive) and C91PL or MT-2 (PJ-34 resistant). Our
results suggested that p53 was functionally reactivated
in all HTLV-I-transformed cells following treatment
with PJ-34, as demonstrated by an increase in p53 (Fig. 6b)










































































































































































































































Fig. 4 PJ-34 causes DNA damage and p53 pathway activation, even in MT-2 and C91PL cells. PJ-34 induces cell apoptosis in most of HTLV-1-
transformed and ATL cells except for C91PL and MT-2 cells. a PBMCs, HTLV-1-transformed (C8166, MT-2, C91PL, MT4), and (b) ATL cells (ATL-MT-1,
ATL-ED, ATL-KOB, ATL-T, ATL-43T, ATL-25, ATL-55T) were treated with DMSO or different concentrations of PJ-34 (5, 10, 25, 50 μM) for 5 days. Cells
were subsequently stained for annexin V and PI and analyzed for apoptosis by FACS analysis. Percentage of increased apoptotic and necrotic cells
in HTLV-1-transformed cells and ATL cell treatment with different amounts of PJ-34 were graphed
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Bax, MDM2, p21, and GADD45α (Fig. 6c–e). One com-
mon target of both p53-dependent G1 arrest and p53-
independent G2 arrest is p21WAF, whose expression was
consistently increased after PJ-34 treatment of HTLV-
I-transformed cells. However, our studies suggest that
the sensitivity of HTLV-I-transformed cells to PJ-34-
induced apoptosis may not be dependent upon p53
signaling since both MT-2 and C91PL cells were
resistant to PJ-34-mediated apoptosis despite reactiva-
tion of p53 in these cells. In addition, some ATLL-
derived HTLV-I-transformed cells such as ED or MT-
1 have no detectable expression of functional p53 and
yet these cells were sensitive to PJ-34 treatment
(Figs. 2 and 4).
Resistance of HTLV-I-transformed cells to PJ-34-induced
apoptosis is associated with defective caspase-3
activation
Disruption of the mitochondrial membrane potential,
ΔΨm, represents a critical step in the activation process
of apoptosis cell death. Therefore, we measured ΔΨm in
MT-4, MT-2, and C91PL cells treated with PJ-34. Our
results suggested that the ΔΨm collapse was pro-
nounced when HTLV-I-transformed cells were treated
with PJ-34, and MT-4 cells were significantly more af-
fected than MT-2 (Fig. 7a). The collapse of the ΔΨm is
usually associated with activation of caspases. Caspase-9
is activated immediately downstream of the mitochon-


























Fig. 5 PARPi olaparib (AZD2281) was used at 25 μM for 3 days on HTLV-I-transformed MT-4, C91PL and MT-2 cells and apoptosis was measured
by annexin V staining and FACS
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formation. In contrast, caspase-8 is traditionally acti-
vated by death receptor signaling. These are referred to
as canonical and non-canonical apoptosis pathways [33].
Caspase-3 is a central mediator in the caspase pathway
and poly (ADP-ribose) polymerase (PARP) is a substrate
of caspase-3 protease activity and its processing is usu-
ally associated with apoptotic cell death. To gain further
insight into the mechanism used by MT-2 and C91PL-
transformed cells to resist PJ-34 toxicity, we analyzed
different markers associated with pro-apoptotic and
anti-apoptotic activities. Although Bcl-xL is overex-
pressed and an important anti-apoptotic factor in
HTLV-I cells [34], the surge in levels of Bax expression
cannot be counteracted by high levels of Bcl-xL, since
the latter does not prevent Bax-mediated apoptosis [35].
Expression of anti-apoptotic Bcl-2 was largely un-
changed after treatment with PJ-34 (Fig. 7b). We then
evaluated whether the observed apoptotic phenotype of
HTLV-I-transformed cells treated with PJ-34 was
dependent upon the mitochondrial pathway by assessing
Bax activation and activation of caspase-3. Surprisingly,
active caspase 3 cleaved products were readily detected
in MT-4-treated cells but not detected in MT-2 and
C91PL cells after exposure to PJ-34 (Fig. 7c). Therefore,
we investigated levels of FLIP and XIAP since these are
known to affect activation of caspase-3, but no differ-
ence was detected for MT-2 and C91PL cells (Fig. 7d).
We amplified and sequenced the cDNA of the caspase-3
gene, but it was wild type in both MT-2 and C91PL. The
reason for the lack of active caspase-3 in MT-2 and
C91PL after PJ-34 treatment is still unclear at the mo-
ment and under further investigation.
Resistance to PJ-34 in HTLV-I-transformed MT-2 cells coin-
cides with increased expression of RelA/p65
We next wanted to understand the molecular mechan-
ism involved in the resistance of HTLV-I-transformed
cells MT-2 and C91PL. This has direct and important
implications for treatment of ATLL patients with PJ-34,
and identification of resistance biomarkers could also
provide new insights for PARPi treatment of breast,
ovarian, and prostate cancer patients. Acquisition of re-
sistance to PARPi can be achieved by genetic alterations
that restore HR functions [36]. Frequently, increased
expression of BRCA1 or p53BP1 has been shown to cor-
relate with resistance to PARPi [37, 38]. However, ex-
pression levels of p53BP1 or BRCA1 were not affected
in HTLV-I-transformed MT-2 or C91PL before or after
PJ-34 treatment (Fig. 8a, b). Increased expression of
miR-107 was associated with PARPi sensitivity [39].
However, analyses of mature miR-107 expression re-
vealed a significant increased expression in both resist-
ant and sensitive HTLV-I-transformed cells (except for
ED) when compared with HTLV-I-negative Jurkat T cells
PJ34
DMSO



































































Fig. 6 PJ-34 causes DNA damage and p53 pathway activation even in MT-2 and C91PL cells. a Western blot of p-H2AX, pS15-p53 and p21 in MT-
4 cells treated with DMSO or PJ-34. Actin was used to confirm equal loading. b Western blot of p53 in MT-2, MT-4 and C91PL cells after
treatment with DMSO or PJ-34. c–e Cells were treated with DMSO or PJ-34 and the changes of p53 target genes Bax (c), MDM2 (d), and
GADD45a (e) were analyzed using real-time RT-PCR. Real-time PCR was performed in duplicate, and data were normalized to GAPDH expression.
Results were presented as mean ± SD from two independent experiments
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(data not shown). Similarly, the expression of PARP1
was not affected in MT-2-treated cells (Fig. 8c). In con-
trast, a significant increase in RelA/p65 was detected
specifically in MT-2 but not MT-4 or C8166 cells follow-
ing treatment with PJ-34, suggesting that canonical NF-
κB activation may play an important role in resistance to
PARPi in these cells.
Discussion
ATLL has a poor clinical outcome and current therapies
have limited long-term benefits, in addition to most pa-
tients with acute or lymphoma ATLL having a short
relapse-free survival. Patients diagnosed with chronic or
smoldering forms of ATLL have a longer life expectancy
but current treatments are ineffective and patients even-
tually progress to the acute type. Numerous studies have
established that cancers with a dysfunction of the HR
DNA repair pathway, also referred to as “BRCAness,”
share characteristics with BRCA1- or BRCA2-mutated
cancer cells and are very sensitive to PARPi [40, 41].
We have previously reported that HTLV-I-transformed
cells have pronounced defects in the homologous
recombination (HR) DNA repair pathway. Additional
studies demonstrated that tumor cells with a defective
base excision repair (BER) pathway are prone to DDSB
accumulation and hypersensitive to PARP targeting [42].
Notably, HTLV-I-transformed cells expressing the viral
oncoprotein Tax have a defective BER pathway [43, 44].
These observations prompted us to investigate the po-
tential benefits of PARPi therapy for ATLL.
In this study, we found a potent anti-proliferative ef-
fect of PARP small inhibitor PJ-34 against HTLV-I-
transformed cells and patient-derived ATLL cells. Re-
duced tumor cell proliferation was demonstrated using
XTT and CFSE staining assays. We showed that HTLV-
I-transformed cells arrested in the G2/M phase of the
cell cycle following treatment with PJ-34 was consistent
with alterations in cyclins and cyclin-dependent kinase
inhibitor (CDKI) expression. The effect of PJ-34 was
time- and dose- dependent and affected both IL-2-
dependent and IL-2-independent HTLV-I-transformed
cells. We further demonstrated that PJ-34 is very effect-
ive against a panel of patient-derived ATLL cell lines,




















































































































Fig. 7 The defect of caspase-3 activation in MT-2 and C91PL contributes to the resistance of PJ-34 in MT-2 and C91PL cells. a MT-4 and MT-2
were treated with DMSO or PJ-34. Cells were subsequently stained with JC-1, and mitochondrial membrane potential (ΔΨm) was measured by
FACS analysis. Representative results of two experiments are shown here. b Western blot of analysis of Bcl-2, Bax, and Bcl-xL in MT-2, C91PL, and
MT-4 after treatment with DMSO or PJ-34. c MT-2, MT-4, and C91PL were treated with DMSO or PJ-34 for 3 days. Then, total cell extracts were
probed for caspase-8, caspase-3, and PARP-1 expression. d Relative expression of FLIP and XIAP were compared using real-time RT-PCR among
resistant cell lines MT-2, C91PL, and other sensitive cell lines. Results were presented as mean ± SD from two independent experiments
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proliferative effects were associated with apoptotic cell
death as shown by annexin V staining and the activation
of caspase-3. We detected a loss of the mitochondrial
membrane potential in HTLV-I cells following PJ-34
treatment, supporting the notion that PJ-34 induces cell
death via the intrinsic mitochondrial pathway. Interest-
ingly, treatment with PARPi PJ-34 resulted in accumula-
tion of DNA breaks and reactivation of the tumor
suppressor p53 transcriptional functions, as demon-
strated by an increased expression of target genes
p21WAF, MDM2, BAX, and GADD45. However, reacti-
vation of p53 was not critical for PJ-34’s effects since
ATLL ED cells do not express p53 and were still sensi-
tive to PJ-34. Interestingly, our studies identified two
HTLV-I-transformed cell lines that were resistant to PJ-
34 treatment: MT-2 and C91PL. We then investigated
differences between MT-4 (PJ-34 sensitive) and MT-2
and C91PL (PJ-34 resistant). We found no specific
pattern of expression for p53BP1 or BRCA1 in PJ-34-
resistant versus sensitive cells. We then investigated ex-
pression of pro- and anti-apoptotic factors. Overall, anti-
apoptotic proteins were not differentially affected but
only MT-4 cells showed an increase in pro-apoptotic
Bax expression. Bcl-xL, a pro-survival member of the
Bcl-2 family, cannot directly inhibit Bax and specifically
inhibits certain upstream BH3-only proteins. This sup-
ports our observation that the upregulation of Bcl-xL
seen in MT-4 cells is unable to inhibit PJ-34-induced
apoptosis and Bax activation, leading to apoptosis. We
found that PJ-34-resistant cells were unable to activate
caspase-3. This was unexpected because we and others
previously demonstrated that MT-2 cells can activate
caspase-3-dependent apoptosis [45–47].
Recently, PARP1 and PARP2 were found to play a
role in sensing stalled or collapsed replication forks
and to recruit the Mre11-Rad50-NBS1 (MRN) complex
for resection and single-stranded DNA (ssDNA) forma-
tion, which allows RAD51 binding onto resected DNA to
initiate HR [48, 49]. Thus, PARP is also involved in HR re-
pair at replication forks and inhibition of PARP leads to
increased DNA lesions that can cause stalling and collapse

















































































































































































Fig. 8 The expressions of known resistant markers in MT-2 and sensitive cell lines. (The defect of caspase 3 activation in MT-2 and C91PL contributes
to the resistance of PJ-34 in MT-2 and C91PL cells.) a, b Relative expression of p53BP1 (a) and BRCA1 (b) was compared using real-time RT-PCR among
resistant cell lines MT-2, C91PL, and other sensitive cell lines. Real-time PCR was performed in duplicate, and data were normalized to GAPDH
expression. Results were presented as mean ± SD from two independent experiments. c Relative expression of p53BP1, p65/RELA, BRCA1, and PARP-1
was compared using real-time RT-PCR among MT-4, C8166, and MT-2 treated with DMSO or 25 μM of PJ-34 for 5 days. Real-time PCR was performed
in duplicate, and data were normalized to GAPDH expression
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suggest that targeting PARPi may be a good approach for
ATLL patients. Combination therapy using PJ-34 and
DNA-damaging agents such as cisplatin has shown prom-
ising results in other cancers and may be considered for a
phase I trial of HTLV-I-associated ATLL. The reprodu-
cible growth arrest in cells from different genetic back-
grounds highlights the potential value of PARPi as
therapeutic agents for the treatment of ATLL.
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